Novavax Inc

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

NVAX

Financials

Novavax Inc

Notizie

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know

Le azioni Novavax salgono mentre un investitore attivista spinge per cambiamenti nel CdA

Novavax nomina Robert Walker responsabile R&S

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Routine Vaccines Okay For Now: Investment Implications Of The Court Decision (XLV)

Jefferies conferma Buy su Novavax, citando la piattaforma adiuvante

Jefferies reiterates Buy on Novavax stock, cites adjuvant platform

Novavax alla Leerink Global Healthcare Conference: cambio strategico di focus/n

Novavax at Leerink Global Healthcare Conference: Strategic Shift in Focus

Novavax alla Conferenza TD Cowen: svolta strategica verso licenze per adiuvante

Novavax at TD Cowen Conference: Strategic Shift to Adjuvant Licensing